Bicara Therapeutics Inc.
BCAX
$11.32
-$0.52-4.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 102.00% | 111.13% | 102.34% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 107.52% | 131.86% | 106.55% | -- | -- |
| Operating Income | -107.52% | -131.86% | -106.55% | -- | -- |
| Income Before Tax | -57.88% | -64.02% | -30.45% | -- | -- |
| Income Tax Expenses | 5,066.67% | 4,200.00% | 3,640.00% | -- | -- |
| Earnings from Continuing Operations | -58.34% | -64.46% | -30.80% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.34% | -64.46% | -30.80% | -- | -- |
| EBIT | -107.52% | -131.86% | -106.55% | -- | -- |
| EBITDA | -107.56% | -131.87% | -106.50% | -- | -- |
| EPS Basic | 96.70% | 76.49% | 54.89% | -- | -- |
| Normalized Basic EPS | 96.70% | 76.49% | 54.89% | -- | -- |
| EPS Diluted | 96.70% | 76.49% | 54.89% | -- | -- |
| Normalized Diluted EPS | 96.70% | 76.49% | 54.89% | -- | -- |
| Average Basic Shares Outstanding | 6,160.20% | 4,857.84% | 2,782.88% | -- | -- |
| Average Diluted Shares Outstanding | 6,160.20% | 4,857.84% | 2,782.88% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |